Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan)
- 1 November 1987
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 113 (6) , 563-566
- https://doi.org/10.1007/bf00390866
Abstract
A total of 190 patients with unresectable non-small cell lung cancer (NSCLC) were analyzed retrospectively using eight pretreatment and three treatment-related prognostic factors in terms of influence on survival. All the patients received chemotherapy with or without chest irradiation, according to the protocol of phase II or phase III trials of the National Cancer Center Hospital Tokyo between April 1980 and December 1985. The eight pretreatment factors selected were performance status, sex, stage, age, histology, and metastasis to brain, bone or, liver. Three treatment-related factors were radiation therapy to the primary site, response to chemotherapy, and treatment period, before or after clinical adminsitration of cis-diamminedichloroplatinum (II) (CDDP). Of the 190 patients, 71 (37.4%) were alive for more than 1 year, but only 17 patients (8.9%) survived 2 years after the initiation of chemotherapy. By univariate analysis, performance status 0–1, female, no metastasis to bone or liver, response to chemotherapy, and treatment period after CDDP were considered to be favorable prognostic factors. By multiregression analysis, performance status, sex, and treatment period after CDDP proved to be important factors for long-term survival. Consideration of these prognostic factors could enable the results of chemotherapy to be more accurately evaluated, and stratification of patients with advanced NSCLC based on performance status and sex before entry into a randomized controlled trial is recommended.Keywords
This publication has 21 references indexed in Scilit:
- Treatment of non-small-cell lung cancer.1986
- Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.Journal of Clinical Oncology, 1986
- Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens.Journal of Clinical Oncology, 1985
- Illusion and reality: practical pitfalls in interpreting clinical trials.Journal of Clinical Oncology, 1984
- IMPORTANCE OF PROGNOSTIC FACTORS IN CANCER CLINICAL-TRIALS1984
- Combination chemotherapy with cisplatin, etoposide, and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC lung cancer working party.1983
- Effect of peplomycin plus carbazilquinone and mitomycin on non-small cell carcinoma of the lung.1983
- Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium)Cancer, 1982
- Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage SchedulesAnnals of Internal Medicine, 1981
- Prognostic Factors for Survival in Patients With Inoperable Lung Cancer2JNCI Journal of the National Cancer Institute, 1980